Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.687
AS - Asia 6.256
EU - Europa 4.717
SA - Sud America 1.037
AF - Africa 179
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 24.900
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.198
SG - Singapore 2.246
CN - Cina 1.383
HK - Hong Kong 958
IT - Italia 862
BR - Brasile 783
RU - Federazione Russa 781
VN - Vietnam 671
SE - Svezia 525
UA - Ucraina 516
DE - Germania 500
IE - Irlanda 474
CA - Canada 402
GB - Regno Unito 269
FR - Francia 220
IN - India 213
FI - Finlandia 150
AT - Austria 135
BD - Bangladesh 126
AR - Argentina 105
KR - Corea 104
TR - Turchia 80
ZA - Sudafrica 63
NL - Olanda 62
IQ - Iraq 61
PK - Pakistan 61
ID - Indonesia 56
MX - Messico 55
JP - Giappone 51
DK - Danimarca 45
PH - Filippine 44
ES - Italia 40
PL - Polonia 39
EC - Ecuador 36
CO - Colombia 34
SA - Arabia Saudita 33
MA - Marocco 31
VE - Venezuela 25
UZ - Uzbekistan 24
BE - Belgio 23
JO - Giordania 17
KE - Kenya 17
PY - Paraguay 16
IR - Iran 14
AE - Emirati Arabi Uniti 13
CH - Svizzera 13
CL - Cile 13
MY - Malesia 13
TN - Tunisia 13
EG - Egitto 12
AU - Australia 11
TH - Thailandia 11
UY - Uruguay 11
TW - Taiwan 10
ET - Etiopia 9
EU - Europa 9
IL - Israele 9
RO - Romania 9
AL - Albania 8
JM - Giamaica 8
PE - Perù 8
SN - Senegal 8
LT - Lituania 7
NP - Nepal 7
PS - Palestinian Territory 7
BO - Bolivia 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
AZ - Azerbaigian 5
LB - Libano 5
OM - Oman 5
PA - Panama 5
RS - Serbia 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
MN - Mongolia 4
AO - Angola 3
BG - Bulgaria 3
BY - Bielorussia 3
GR - Grecia 3
HN - Honduras 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MK - Macedonia 2
NG - Nigeria 2
Totale 24.871
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.846
Singapore 1.249
Woodbridge 1.187
Ashburn 1.125
Hong Kong 935
Houston 681
Fairfield 676
San Jose 557
Jacksonville 523
Dublin 441
Chandler 414
Wilmington 401
Dearborn 335
Seattle 300
Frankfurt am Main 297
New York 297
Cambridge 255
Toronto 224
Princeton 218
The Dalles 214
Santa Clara 207
Chicago 203
Milan 189
Beijing 180
Ho Chi Minh City 178
Los Angeles 167
Hanoi 154
Dallas 146
Hefei 134
Vienna 122
Lauterbourg 109
Nanjing 109
Altamura 106
Lawrence 104
Lachine 91
Seoul 91
Shanghai 91
Moscow 77
Council Bluffs 72
São Paulo 71
Buffalo 51
Rome 50
Boardman 49
Fremont 49
Guangzhou 48
Andover 46
Helsinki 44
San Diego 44
Ottawa 41
London 38
Nanchang 38
Rio de Janeiro 37
Hebei 34
Munich 33
Washington 32
Changsha 31
Orem 30
Warsaw 30
Da Nang 29
Jakarta 29
Jiaxing 29
Shenyang 29
Tianjin 29
Tokyo 29
Baghdad 25
Johannesburg 25
Detroit 23
Salt Lake City 23
Brussels 22
Chennai 22
Huizen 22
Kunming 22
Nuremberg 22
Lahore 21
Pune 21
Tashkent 20
Brooklyn 19
Falls Church 19
Montreal 19
Atlanta 18
Norwalk 18
Ankara 17
Hangzhou 17
Lissone 17
Manchester 17
San Francisco 17
Amsterdam 16
Amman 15
Belo Horizonte 15
Brasília 15
Haiphong 15
Phoenix 15
Bologna 14
Dong Ket 14
Mexico City 14
Nairobi 14
Quito 14
Riyadh 14
Shenzhen 14
Buenos Aires 13
Totale 16.323
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 577
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 538
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 427
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 404
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 393
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 377
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 358
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 355
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 338
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 332
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 308
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 297
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 291
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 289
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 283
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 282
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 276
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 264
Synchronous early-stage endometrial and ovarian cancer 264
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 261
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 261
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 258
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 251
Uterine leiomyosarcoma: analysis of treatment failures and survival 250
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 250
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 248
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 245
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 237
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 236
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 236
Endometriomas: Their ultrasound characteristics 232
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 231
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 229
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 229
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 228
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 224
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 223
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 223
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 221
Endometrial stromal sarcoma: analysis of treatment failures and survival 220
Fertility outcomes in stage I ovarian immature teratomas 218
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 218
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 218
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 215
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 215
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 214
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 214
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 213
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 210
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 209
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 209
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 208
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 207
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 207
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 206
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 204
Optimal treatment of early-stage ovarian cancer 203
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab 202
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 202
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 202
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 200
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 200
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 198
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 196
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 196
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 195
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 195
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 192
Antiemetic efficacy of granisetron in patients with gynecological malignancies 192
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 191
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 190
Color Doppler ultrasound in the preoperative assessment of adnexal masses 190
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 189
Tumor volume as risk factor for nodal diffusion in endometrial cancer 186
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 185
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 184
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 182
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 182
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 181
Clinically oriented three-step strategy for assessment of adnexal pathology 172
Ifosfamide in the treatment of malignant epithelial ovarian tumors 171
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 170
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 170
Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? 170
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 170
Brain metastases from endometrial carcinoma 169
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 168
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 167
Second-look laparotomy in the management of fallopian tube carcinoma 166
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 162
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 161
Alpha-fetoprotein in the management of germ cell tumors of the ovary 155
Fertility-sparing surgery in uterine leiomyosarcoma 154
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 154
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 150
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: An Italian multicentric retrospective analysis 148
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 147
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 146
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer 146
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer 144
Totale 22.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.711
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.711
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021268 0 0 0 0 0 0 0 0 0 0 109 159
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/20268.597 860 594 763 891 1.016 511 1.147 614 823 917 461 0
Totale 25.307